Golden
SyntheX

SyntheX

A biotechnology and pharmaceutical company headquartered in San Francisco, California that was founded in 2016 by Charly Chahwan and Maria Soloveychik developing treatments for cancer and other diseases.

All edits

Edits 3 days ago
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI 3 days ago
Edits made to:
Article (+16/-16 characters)

Article

The SyntheX drug developmentdrug development technology can be used for creating drug products for use in oncology, membrane proteins, orphan diseases, antibiotic development, neuroinflammation, and immunology.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI 3 days ago
Edits made to:
Article (+17/-17 characters)

Article

Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancer, HR -driven pancreatic cancerpancreatic cancer, non-small cell lung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI 3 days ago
Edits made to:
Article (+11/-11 characters)

Article

Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancer, HR -driven pancreatic cancer, non-small cell lung cancerlung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI 3 days ago
Edits made to:
Article (+11/-11 characters)

Article

SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug designdrug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI 3 days ago
Edits made to:
Article (+12/-12 characters)

Article

Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancerliver cancer, HR -driven pancreatic cancer, non-small cell lung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.

Dawson Sewell
Dawson Sewell edited 3 days ago
Edits made to:
Description (+1/-12 characters)
Article (+575 characters)
Topic thumbnail

SyntheX

SyntheX is aA biotechnology and pharmaceutical company headquartered in San Francisco, California that was founded in 2016 by Charly Chahwan and Maria Soloveychik developing treatments for cancer and other diseases.

Article

The SyntheX drug development technology can be used for creating drug products for use in oncology, membrane proteins, orphan diseases, antibiotic development, neuroinflammation, and immunology.

Compound development

Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancer, HR -driven pancreatic cancer, non-small cell lung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.

Edits on 21 Jan 2020
Golden AI
Golden AI edited on 21 Jan 2020 4:53 pm
Edits made to:
Infobox (+1 properties)

Infobox

Investors
Edits on 16 Dec 2019
Golden AI
Golden AI edited on 16 Dec 2019 4:10 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 2 Jun 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 2 Jun 2019 5:05 am
Edits made to:
Article (+17/-17 characters)

Article

SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria SoloveychikMaria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.

Will Suter
Will Suter approved a suggestion from Golden's AI on 2 Jun 2019 4:57 am
Edits made to:
Article (+14/-14 characters)

Article

SyntheX is a biotechnology and pharmaceutical company that was founded by Charly ChahwanCharly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.

Edits on 30 May 2019
Golden AI
Golden AI edited on 30 May 2019 9:28 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 30 May 2019
Golden AI
Golden AI edited on 30 May 2019 4:14 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 26 May 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 26 May 2019 12:37 am
Edits made to:
Article (+14/-14 characters)

Article

On April 20, 2017 SyntheX closed their seed funding round with $6.2 million in seed round funding from Morgan Noble, SOSV, Oriza VenturesOriza Ventures, and 8VC.

Edits on 23 May 2019
Golden AI
Golden AI edited on 23 May 2019 11:52 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 7 Mar 2019
Golden AI
Golden AI edited on 7 Mar 2019 10:36 pm
Edits made to:
Infobox (+1 properties)

Infobox

Accelerator
Edits on 21 Feb 2019
Melanie Manipula
Melanie Manipula approved a suggestion from Golden's AI on 21 Feb 2019 2:11 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 29 Jan 2019
Golden AI
Golden AI edited on 29 Jan 2019 6:49 pm
Edits made to:
Infobox (+2 properties)

Infobox

Incubator Batch
Founded
2016
Edits on 28 Jan 2019
Golden AI
Golden AI edited on 28 Jan 2019 2:22 pm
Edits made to:
Infobox (+3 properties)

Infobox

Incubator Batch
IndieBio 03
Place of incorporation
Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 9:31 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 16 Jan 2019
Melanie Manipula
Melanie Manipula approved a suggestion from Golden's AI on 16 Jan 2019 9:00 pm
Edits made to:
Infobox (+5 properties)